Biogen Idec Plans Jump to Phase 3 Trial for Alzheimer’s Drug Based on Early-Stage Data

Biogen Idec Plans Jump to Phase 3 Trial for Alzheimer’s Drug Based on Early-Stage Data
Biogen Idec, the company behind several of today's most widely sold multiple sclerosis drugs, has been developing a novel treatment for Alzheimer's disease, called BIIB037, which has shown great potential in blocking beta amyloid -- one of the hallmarks of this common form of dementia -- and improving cognitive function. Just recently, the company's chief of research announced they are already strategizing moving the drug to a Phase III trial based on the positive results of a small-scale early stage study. The company's news boosted shares by 6 percent, according to midday trading on the Nasdaq. Douglas E. Williams, Ph.D., Biogen's Executive Vice President of Research and Development, said during the Deutsche Bank BioFEST conference that the company's plans to start a Phase III study as soon as possible is based on the encouraging findings in a Phase 1b trial of the drug. BIIB037 was administered in patients with minor symptoms of Alzheimer's disease, and in asymptomatic patients who may be at risk for developing the disease. While the drug was noted to cause signs of brain swelling and tiny hemorrhages, the researchers claimed th
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *